SCHEMBL9904381

SCHEMBL9904381

Cc1ccc(S(=O)(=O)n2cc(I)c3cc(-c4c(F)cccc4Cl)ccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.41
UBE2N P61088 1/20 0.41
HTR6 P50406 6/20 0.41
ALDH1A1 P00352 1/20 0.39
RECQL P46063 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALK Q9UM73 1/20 0.37
KDM1A O60341 1/20 0.37
KLK7 P49862 2/20 0.37
BRD4 O60885 2/20 0.37
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9905029 0.92 L3MBTL1 (0.47) L3MBTL1KDM4EUBE2NHTR6ALK
SCHEMBL9904433 0.80 L3MBTL1 (0.41) L3MBTL1KDM4EUBE2NHTR6MAPT
SCHEMBL9942502 0.79 L3MBTL1 (0.47) L3MBTL1KDM4EUBE2NHTR6ALK
SCHEMBL9904636 0.79 L3MBTL1 (0.50) L3MBTL1KDM4EUBE2NHTR6CYP3A4
SCHEMBL31315847 0.78 KLK7 (0.48) L3MBTL1KDM4EUBE2NHTR6CYP3A4
SCHEMBL31315863 0.78 KDM1A (0.50) L3MBTL1KDM4EUBE2NHTR6ALDH1A1
SCHEMBL31315843 0.78 KDM4E (0.52) L3MBTL1KDM4EUBE2NHTR6ALK
SCHEMBL31593168 0.78 KDM4E (0.52) L3MBTL1KDM4EUBE2NHTR6ALK
SCHEMBL31315854 0.77 KDM4E (0.46) L3MBTL1KDM4EUBE2NHTR6ALDH1A1
SCHEMBL9904551 0.75 PIM1 (0.47) L3MBTL1KDM4EUBE2NHTR6KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 L3MBTL1 1581/4885KDM4E 539/4885UBE2N 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.